Aerie’s glaucoma drug journey ends in $770M sale to Alcon
Bio Pharma Dive
AUGUST 23, 2022
The biotech successfully brought two medicines to market, but shares have lost most of their value amid sluggish sales.
Esperion lays off nearly half its workforce as heart drug sales disappoint
Bio Pharma Dive
OCTOBER 18, 2021
The company hopes a "streamlined" sales force can turn around a drug launch that's failed to meet expectations amid tough competition from rival medicines.
Sales 
284
284 Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Pfizer’s Covid-19 vaccine sales forecasts upgraded with sales of $37bn in 2022
Pharmaceutical Technology
FEBRUARY 21, 2023
Pfizer and BioNTech’s Covid-19 vaccine, Comirnaty, had a phenomenal year with forecast sales of $37bn in 2022. Comirnaty is the leading prophylactic vaccine for Covid-19 and is expected to generate an additional $2.8bn in sales in 2022 compared to GlobalData’s H1 2022 forecast. Comirnaty is the first globally approved Covid-19 vaccine.
Sales 246
246 
Pfizer forecasts $15B sales boost from coronavirus vaccine orders
Bio Pharma Dive
FEBRUARY 2, 2021
The estimate for 2021 sales, which Pfizer splits with partner BioNTech, would make the vaccine one of the highest-selling medicines in the industry.
Sales 236
236 
Merck reports rise in group net sales in fiscal 2022
Pharmaceutical Technology
MARCH 2, 2023
Merck has reported an increase in group net sales by 12.9% The growth in sales was driven by all regions and business sectors, particularly Life Science. in group sales in fiscal 2022. Additionally, due to the acquisition of Exelead, a biopharmaceutical contract development and manufacturing company, sales increased by 0.4%.
Sales 245
245 
Lilly and ProQR to expand genetic medicine development agreement
Pharmaceutical Technology
DECEMBER 23, 2022
Eli Lilly and Company has expanded a licencing and partnership agreement with ProQR Therapeutics to discover, develop and market new genetic medicines. The post Lilly and ProQR to expand genetic medicine development agreement appeared first on Pharmaceutical Technology.
Genetics 328
328 
Novo obesity drug sales lag as manufacturing problems persist
Bio Pharma Dive
NOVEMBER 2, 2022
Manufacturing problems continue to weigh on Novo’s Wegovy launch as competition looms from Eli Lilly’s fast-selling diabetes medicine Mounjaro.
Manufacturing 301
301 
Jan Aushadhi Kendras report 6.7 per cent growth in sales in August
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 2, 2024
per cent growth in sales of generic medicines at Maximum Retail Price (MRP) value in the month of August, as compared to the sales same month a year […]
Sales 189
189 
AstraZeneca, Avillion get FDA approval for new ‘rescue’ drug for asthma
Bio Pharma Dive
JANUARY 11, 2023
Airsupra joins a growing portfolio of new drugs that are helping the British drugmaker offset wilting sales of older respiratory medicines like Pulmicort.
FDA Approval 322
322 
Seagen shares sink as sales outlook of cancer drug disappoint
Bio Pharma Dive
FEBRUARY 10, 2022
The biotech is predicting sales of Tukysa, its new breast cancer drug, will remain flat or fall in 2022 as competition increases from AstraZeneca's rival medicine Enhertu.
Sales 167
167 
J&J pitches investors on sales growth from cancer, immune disease drugs
Bio Pharma Dive
DECEMBER 5, 2023
The company expects its pharmaceutical division to deliver 20 new medicines through the end of the decade, including several it believes could earn peak annual sales of more than $5 billion.
Sales 167
167 
Bluebird resumes marketing gene therapy in Europe
Bio Pharma Dive
JULY 9, 2021
Zynteglo sales have been on hold since February, when a patient in a clinical trial of another, related Bluebird medicine developed leukemia.
Gene Therapy 274
274 
Blueprint Medicines announces financing partnerships for $1.25bn
Pharmaceutical Technology
JULY 1, 2022
Blueprint Medicines has entered strategic financing partnerships for up to $1.25bn with life sciences-focused investors Sixth Street and Royalty Pharma. The partnership with Royalty Pharma monetises royalty payments obtainable from net sales of Gavreto by Roche outside of the US, excluding Greater China.
Medicine 147
147 
Eli Lilly’s earnings, shares lifted by obesity drug sales
Bio Pharma Dive
FEBRUARY 6, 2025
The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for its weight loss medicines in January.
Sales 167
167 
Looking past Humira, AbbVie boosts sales forecasts for successor drugs
Bio Pharma Dive
JANUARY 11, 2023
Competition to Humira will weigh on AbbVie, but the pharma has laid out ambitious expectations for fast growth from its medicines Skyrizi and Rinvoq.
Sales 184
184 
Novartis to consider sale or separation of Sandoz business
Bio Pharma Dive
OCTOBER 26, 2021
The generic drug unit has struggled in recent years, while Novartis has moved to focus more narrowly on higher-margin branded medicines.
Generic Drugs 176
176 
GLP-1 receptor agonist sales expected to reach $125bn by 2033
Pharmaceutical Technology
MAY 15, 2024
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of incretin mimetic medicines for the treatment of Type 2 diabetes and obesity.
Sales 162
162 
Novartis said to be eyeing sale of ophthalmology, respiratory units
pharmaphorum
NOVEMBER 16, 2022
Novartis has already spun out its eyecare business Alcon, and is now considering the sale of its ophthalmology and respiratory medicines businesses as it continues a narrowing of its focus, according to media reports. Meanwhile, Lucentis sales have been in decline as a result of biosimilar competition, contracting 11% to $1.55
Sales 124
124 
Trailblazing Healthcare Sales Agent, Sarin, is Awarded iDE’s “40 Under 40” for Her Impact in Rural Bangladesh
Pharma Mirror
JUNE 15, 2023
Sarin Akter, a dynamic healthcare sales agent from Moulavibazar, Bangladesh, has been recently honored with iDE’s esteemed “40 Under 40” award. Her skills were honed through training from iDE, which equipped her with effective sales strategies and the ability to counsel on a range of health issues.
Sales 130
130 
Belharra and Genentech partner for small molecule medicines development
Pharmaceutical Technology
JANUARY 4, 2023
Belharra Therapeutics and Roche Group member Genentech have announced a partnership for the discovery and development of new small molecule medicines across several therapeutic areas. Additionally, Belharra will receive a tiered royalty on the sale of products that are a result of the collaboration by Genentech.
Medicine 130
130 
Sanofi, Regeneron win FDA nod for Dupixent in chronic hives
Bio Pharma Dive
APRIL 18, 2025
The partners overcame an earlier rejection to win a seventh use for Dupixent, though some analysts are skeptical of its sales potential compared to other emerging medicines for the condition.
Sales 162
162 
Moderna and Generation Bio partner for genetic medicines development
Pharmaceutical Technology
MARCH 24, 2023
Moderna has entered a strategic partnership with Generation Bio for the development of non-viral genetic medicines. Moderna’s biological and technical expertise will be combined with core technologies of the non-viral genetic medicine platform from Generation Bio.
Genetics 130
130 
UK-based company selling breakthrough cannabis-based medicines now supplying the US
Outsourcing Pharma
MAY 29, 2024
UK based Celadon Pharmaceuticals Plc, that specializes in the development, production, and sale of breakthrough cannabis-based medicines, announced that it has begun shipping to the US.
Medicine 105
105 
STAT+: Regeneron’s Eylea sales dip, as competition looms
STAT News
JANUARY 9, 2023
Wall Street had been watching sales figures closely, for fear that competition from biosimilars — a form of generic — and new medicines from rival drugmakers could cut into the sales that have fueled Regeneron’s growth since Eylea was approved in 2011. Continue to STAT+ to read the full story…
Sales 105
105 
Centre puts onus on SLAs to take action against e-pharmacies for violation of D&C Act and Rules
AuroBlog - Aurous Healthcare Clinical Trials blog
MARCH 23, 2023
With the chemists and druggists across the country opposing the sale of drugs through online, the Central government is taking a stand that the sale of medicines should be strictly under the provisions of the existing regulations and the State Licensing Authorities (SLAs) are legally empowered to act against violation of the legal provisions.
Pharmacy 188
188 
Obesity represents a catastrophic failure of government policy, public health, and medicine
World of DTC Marketing
JUNE 5, 2021
Research published by the World Health Organization found that a rise in fast food sales correlated to a rise in body mass index, and Americans are notorious for their fast-food consumption ? The post Obesity represents a catastrophic failure of government policy, public health, and medicine.
Medicine 193
193 
Blockchain: Ready to revolutionise medicinal cannabis research?
pharmaphorum
JUNE 29, 2021
” Therefore human beings have known the medicinal properties of cannabis since Emperor Marcus Aurelius was jotting down pithy advice for stoics between battles on the Rhine. Thus a blockchain can track anything from the sale and ownership of a few dogecoins to the entire life cycle of a sensitive clinical trial.
Medicine 130
130 
MHRA bans OTC sale of codeine after recreational abuse reports
Pharmaceutical Technology
FEBRUARY 21, 2024
Codeine linctus has been reclassified from a pharmacy-only medicine to a prescription-only medicine in the UK.
Sales 130
130 
Sandoz bulks up ahead of possible sale with Coalesce buy
pharmaphorum
MARCH 14, 2022
This morning, Sandoz announced it has acquired medical and drug delivery device specialist Coalesce Product Development, bolstering its capabilities for the development of respiratory medicines and ‘complex’ generics. The post Sandoz bulks up ahead of possible sale with Coalesce buy appeared first on.
Sales 104
104 
Scribe and Prevail partner for CRISPR-based genetic medicines
Pharmaceutical Technology
MAY 17, 2023
Under the deal, Prevail obtains exclusive rights to use Scribe’s CRISPR X-Editing (XE) technologies to develop the medicines. The deal will see the integration of Scribe’s new CRISPR by Design approach and Prevail’s expertise in developing genetic medicines for neurological disorders for specific genetic targets.
Genetics 130
130 
Blueprint boosts Ayvakit peak sales estimate to $2B as key rare disease expansion accelerates
Fierce Pharma
FEBRUARY 14, 2024
With another quarter exceeding analysts’ expectations, Blueprint Medicines has raised its peak sales estimate for rare disease drug Ayvakit to $2 billion. With another quarter exceeding analysts’ expectations, Blueprint Medicines has raised its peak sales estimate for rare disease drug Ayvakit to $2 billion.
Sales 89
89 
STAT+: Amid fears of superbugs, sales of antibiotics used in food-producing livestock barely declined last year
STAT News
DECEMBER 12, 2022
Amid fears of superbugs, the sale of medically important antibiotics given to food-producing livestock declined by less than 1% overall in the U.S. Meanwhile, the sale and distribution of macrolides, which represented 9% of overall domestic sales of such medicines, rose by 21%.
Sales 98
98 
GSK stays optimistic on vaccines amidst US and China woes
Pharmaceutical Technology
FEBRUARY 5, 2025
While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth.
Vaccination 147
147 
Innovative Medicines Fund and the opportunity for ICSs to mobilise NICE approvals
pharmaphorum
OCTOBER 28, 2022
In June, NHSE and NICE published details on the Innovative Medicines Fund, which will help improve patient access to cutting-edge medicines, with a particular focus on rare diseases, and ensure global pharmaceutical and biotech organisations continue to prioritise the UK as a launch destination. Angela McFarlane ?,
Medicine 122
122 
Rebranded Servier eyes €3bn in cancer drug sales by 2030
pharmaphorum
OCTOBER 6, 2022
Servier is already in the process of transforming itself into a much bigger player in cancer, and has just tripled its sales objectives for the category. ” Its updated plan predicts group sales of €6 billion in 2025 and operating profits of around €1.3 billion, rising to €8 billion and approximately €2.4
Sales 98
98 
GSK to acquire BELLUS Health for $2bn
Pharmaceutical Technology
APRIL 19, 2023
GSK expects that the BELLUS Health acquisition will boost its speciality medicines and respiratory pipeline. There are no approved medicines for the disease in the EU and the US. Camlipixant, a novel, highly selective P2X3 antagonist, has the potential to be a best-in-class treatment with significant sales potential.
Medicine 243
243 
Top 3 Best-Selling Eye Drugs by Recent Sales Data
XTalks
JANUARY 3, 2025
In this blog, we delve into the recent sales data to highlight the top three best-selling eye drugs in 2023. Lets take a closer look at Eylea, Vabysmo and Lucentis the ophthalmology drugs that led the pack in recent sales figures. Related: Top 30 Drugs to Watch in 2024: Insights from 2023 Sales Data 1. billion, down from $1.50
Sales 85
85 
Jazz Pharma Announces $100 Million “Green” Manufacturing Plant for Cannabis-Based Medicines
XTalks
MARCH 29, 2022
Jazz Pharmaceuticals has broken ground on a new $100 million manufacturing plant for cannabis-based medicines in the UK. The 60,000-square-foot facility was specially designed to support the company’s two regulatory-approved cannabis-based medicines and offer capacity for future drugs currently under development.
Medicine 111
111 
Pfizer sets up DTC marketing platform as Q1 sales beat expectations
Fierce Pharma
MAY 1, 2024
Following the lead of Eli Lilly, Pfizer will establish a direct-to-consumer service, selling some of its medicines online and avoiding industry middlemen. Following the lead of Eli Lilly, Pfizer will establish a direct-to-consumer service, selling some of its medicines online and avoiding industry middlemen.
Sales 107
107 
7 commercial, sales, and marketing predictions for 2023
pharmaphorum
DECEMBER 23, 2022
Rarely are organisations able to view HCP relationships holistically – across clinical, medical, and sales – or reap the benefits of creating a unified understanding of the customer. In 2023, omnichannel behaviours will directly influence incentive compensation models by correlating successful engagement data to successful sales outcomes.
Sales 105
105 
Supply chain middlemen ‘pocket half of US branded medicine spending’
pharmaphorum
JANUARY 13, 2022
In 2020, over half of total spending on brand medicines went to the supply chain, middlemen and other stakeholders, overtaking the amount going to drug manufacturers for the first time, according to a new study. ” The post Supply chain middlemen ‘pocket half of US branded medicine spending’ appeared first on. .
Branding 111
111 
Let's personalize your content